Enable Accessibility Enable Accessibility

Half Yearly Report

August 1, 2014

Shire plc (the “Company”) (LSE: SHP, NASDAQ: SHPG), in accordance with the Financial Conduct Authority's Disclosure Rules and Transparency Rules, is publishing today its Half Yearly Report for the six months ended June 30, 2014.

It should be noted that on July 18, 2014 the Company previously announced its results in respect of the same period.

For further information please contact:

Investor Relations 
Jeff Poulton
 jpoulton@shire.com
+1 781 482 0945
 
Sarah Elton-Farr
 seltonfarr@shire.com
+44 1256 894 157
  
Media 
Stephanie Fagan
sfagan@shire.com
+1 781 482 0460

Gwen Fisher
gfisher@shire.com
+1 484 595 9836

Notes to editors

Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

Click here for the PDF version of this press release.